Anupam Rasayan completes acquisition of 48.2% controlling stake in Bliss GVS Pharma
Anupam Rasayan India · Chemicals & Petrochemicals
Key highlights
- Consideration paid on September 28, 2026, at ₹299 per share via Mates Visa Consultancy, a wholly owned subsidiary
- Funded by a ₹300 crore term loan and approximately ₹1,450 crore raised through non-controlling, non-voting instruments from investors led by Bain Capital
- Combined platform pro-forma revenue of more than ₹4,000 crore is expected, from Anupam standalone ₹1,676 crore, Tanfac ₹711 crore, Jayhawk ₹722 crore and Bliss GVS ₹927 crore
Why it's rated notable: amount is ₹500 crore or more
Figures checked against the filing by a second AI read, which corrected the first summary. About the business, not the share price.
Original filing
Announcement under Regulation 30 (LODR)-Press Release / Media Release
Read the filing on BSE (PDF) →Companies guiding to strong growth
Ranked by management's own guidance on revenue and margins — not by us.
Aerospace & Defense
Sign up free to see all 6 →
See full rankingsRank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
More from Anupam Rasayan India
- Board / shareholder meeting outcomeNotableAnupam Rasayan India Ltd approves 23rd AGM, dividend record date, Tanfac share acquisition
- Order winNotableAnupam Rasayan signs six-year supply contract with US specialty metal firm
- Fundraise / allotmentMajor developmentAnupam Rasayan India Ltd credit rating updated by Crisil Ratings Limited
- Fundraise / allotmentNotableAnupam Rasayan India Ltd announces FY26 results, dividend, auditors, and acquisition plans
- Acquisition / mergerNotableAnupam Rasayan board approves acquisition of up to 74.20% control of Bliss GVS Pharma
Other acquisition / merger filings this fortnight
- Acquisition / mergerKothari PetrochemicalsKothari Petrochemicals Limited announces approval of Scheme of Amalgamation
- Acquisition / mergerKothari PetrochemicalsKothari Petrochemicals Limited approves Scheme of Amalgamation on Nov 13, 2026
- Acquisition / mergerFusion CXFusion CX Limited announces board meeting outcomes and key appointments
- Acquisition / mergerFusion CXFusion CX Limited announces latest financial results, dividends, and board appointments
- Acquisition / mergerFusion CXFusion CX Limited announces Q2 FY27 results, dividends, auditor and director appointments
- Acquisition / mergerKothari Sugars & ChemicalsKothari Sugars and Chemicals Ltd announces approval of Scheme of Amalgamation
Potential multibaggers · Q2 FY27
Potential multibaggers in Chemicals & Petrochemicals
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Summary written by Arthneeti from the company's filing with the stock exchange; check the original filing for full details. Arthneeti is a research and analytics platform, not a SEBI-registered investment adviser, and nothing here is a recommendation to buy or sell.